ARVN Arvinas, Inc. Stock Quote

ARVN [NASD]

Index	-	P/E	-	EPS (ttm)	-4.17	Insider Own	2.10%	Shs Outstand	53.00M	Perf Week	-0.78%
Market Cap	2.07B	Forward P/E	-	EPS next Y	-5.10	Insider Trans	-9.25%	Shs Float	47.04M	Perf Month	0.96%
Income	-213.40M	PEG	-	EPS next Q	-1.04	Inst Own	91.00%	Short Float	9.79%	Perf Quarter	-34.09%
Sales	65.40M	P/S	31.69	EPS this Y	-26.60%	Inst Trans	4.96%	Short Ratio	9.26	Perf Half Y	-47.33%
Book/sh	13.65	P/B	3.08	EPS next Y	-22.20%	ROA	-16.10%	Target Price	101.22	Perf Year	-45.34%
Cash/sh	29.01	P/C	1.45	EPS next 5Y	-	ROE	-29.40%	52W Range	34.90 - 108.46	Perf YTD	-48.76%
Dividend	-	P/FCF	3.87	EPS past 5Y	-57.30%	ROI	-	52W High	-60.74%	Beta	1.96
Dividend %	-	Quick Ratio	6.10	Sales past 5Y	47.60%	Gross Margin	-	52W Low	22.01%	ATR	3.04
Employees	280	Current Ratio	6.10	Sales Q/Q	340.00%	Oper. Margin	-	RSI (14)	49.32	Volatility	7.80% 7.13%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-42.00%	Profit Margin	-	Rel Volume	0.47	Prev Close	42.09
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	496.90K	Price	42.58
Recom	1.80	SMA20	2.69%	SMA50	-6.95%	SMA200	-37.51%	Volume	232,665	Change	1.16%

Jun-21-22

Initiated

Jefferies

Hold

$42

May-09-22

Downgrade

Wedbush

Outperform → Neutral

Apr-28-22

Initiated

Credit Suisse

Outperform

$104

Apr-06-22

Initiated

Morgan Stanley

Equal-Weight

$65

Feb-11-22

Resumed

BMO Capital Markets

Outperform

$125

Feb-10-22

Initiated

Wells Fargo

Overweight

$98

Jan-19-22

Initiated

Goldman

Buy

$157

Dec-07-21

Initiated

Cowen

Outperform

Oct-14-21

Initiated

SVB Leerink

Outperform

$115

Sep-30-21

Initiated

Stifel

Buy

$115

Sep-09-21

Initiated

BofA Securities

Buy

$110

May-21-21

Initiated

UBS

Buy

$123

Apr-21-21

Initiated

Truist

Buy

$150

Mar-31-21

Initiated

BMO Capital Markets

Outperform

$101

Dec-14-20

Upgrade

Oppenheimer

Perform → Outperform

Jun-01-20

Upgrade

Citigroup

Neutral → Buy

$45

May-12-20

Initiated

Oppenheimer

Perform

Dec-19-19

Initiated

H.C. Wainwright

Buy

$50

Nov-25-19

Initiated

Guggenheim

Buy

$50

Oct-24-19

Upgrade

Goldman

Neutral → Buy

$23 → $38

Jun-27-22 08:52AM	Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar? Zacks
Jun-02-22 04:00PM	Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference GlobeNewswire
Jun-01-22 08:00AM	Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations GlobeNewswire
May-10-22 08:26AM	Investing in These 3 Healthcare Stocks Could Double Your Money, Says Credit Suisse TipRanks +9.78%
May-09-22 10:00AM	GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration PR Newswire -15.63%
May-05-22 08:15AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates Zacks -9.94%
07:00AM	Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
May-03-22 07:00AM	Arvinas to Present at Bank of America Securities 2022 Healthcare Conference GlobeNewswire
Apr-26-22 03:01PM	Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks -7.85%
Mar-04-22 07:00AM	Arvinas to Present at Upcoming Investor Conferences GlobeNewswire
Mar-02-22 11:22AM	Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag Zacks
Feb-28-22 08:25AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
Feb-25-22 10:14AM	Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Feb-24-22 10:15AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates Zacks
Feb-17-22 08:00AM	Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer GlobeNewswire
04:40AM	Despite shrinking by US$144m in the past week, Arvinas (NASDAQ:ARVN) shareholders are still up 227% over 3 years Simply Wall St.
Feb-15-22 12:50PM	Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients Benzinga
Feb-14-22 06:04PM	Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting GlobeNewswire
Feb-03-22 04:30PM	Arvinas to Present at Upcoming Investor Conferences GlobeNewswire
Jan-31-22 09:04AM	Goldman Sachs Bets on These 3 Strong Buy Stocks TipRanks +8.48%
Jan-06-22 05:38PM	Canton Hathaway, LLC Buys Amplify Lithium & Battery Technology ETF, Raytheon Technologies ... GuruFocus.com
Dec-13-21 04:38PM	Deutsche Dws Variable Series Ii Buys Dynatrace Inc, CarGurus Inc, National Vision Holdings Inc, ... GuruFocus.com
Dec-12-21 11:00AM	Should I Avoid Arvinas, Inc. (ARVN)? Insider Monkey
Dec-10-21 10:40AM	Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients Benzinga -6.83%
08:10AM	Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer GlobeNewswire
Nov-19-21 09:55AM	Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium GlobeNewswire
04:24AM	What Kind Of Shareholders Hold The Majority In Arvinas, Inc.'s (NASDAQ:ARVN) Shares? Simply Wall St.
Nov-18-21 10:28AM	Notable Arvinas Insider Trades $2.0M In Company Stock Benzinga
Nov-16-21 10:24AM	Notable Arvinas Insider Makes $11M Sale Benzinga
08:50AM	4 Stocks Insiders Are Selling Benzinga
Nov-10-21 11:35AM	Notable Arvinas Insider Trades $16M In Company Stock Benzinga -5.39%
07:00AM	Arvinas to Present at Stifel 2021 Virtual Healthcare Conference GlobeNewswire
Nov-03-21 08:25AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM	Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Oct-20-21 06:05PM	Is Arvinas, Inc. (ARVN) Going to Burn These Hedge Funds? Insider Monkey
04:02PM	Neurona Therapeutics Appoints Brad Margus to its Board of Directors GlobeNewswire
Sep-01-21 07:00AM	Arvinas to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Aug-15-21 03:04AM	Analysts Just Made An Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts Simply Wall St.
Aug-09-21 09:47AM	Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas PR Newswire
09:16AM	Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas PR Newswire
09:16AM	Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas CNW Group
Aug-05-21 10:25AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-01-21 10:54AM	Betting on Momentum? 2 Strong Buy Stocks to Keep an Eye On TipRanks
Jul-29-21 08:50AM	Recent Price Trend in Arvinas, Inc. (ARVN) is Your Friend, Here's Why Zacks
Jul-27-21 03:02PM	Analysts Estimate Arvinas, Inc. (ARVN) to Report a Decline in Earnings: What to Look Out for Zacks
12:00PM	All You Need to Know About Arvinas, Inc. (ARVN) Rating Upgrade to Buy Zacks
Jul-26-21 03:53AM	Arvinas, Inc. (ARVN) Moves 13% Higher: Will This Strength Last? Zacks
Jul-23-21 11:06AM	Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy Zacks +12.97%
Jul-22-21 03:21PM	Why Arvinas Jumped 10% Today Motley Fool +8.97%
08:06AM	Pfizer to pay at least $1 billion to develop, commercialize Arvinas' investigational breast-cancer therapy MarketWatch
07:00AM	Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471 GlobeNewswire
06:32AM	Arvinas Stock Surges on Pfizer Breast Cancer Treatment Deal TheStreet.com
Jul-13-21 12:32PM	Hedge Funds Are Dumping Arvinas, Inc. (ARVN) Insider Monkey
Jul-08-21 02:03AM	How Many Arvinas, Inc. (NASDAQ:ARVN) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Jun-07-21 05:19PM	Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven GlobeNewswire +5.86%
Jun-03-21 07:00AM	Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference GlobeNewswire
May-21-21 04:03PM	Arvinas Stock Pops On Buy Rating As Biotech Takes On 'Undruggable Targets' Investor's Business Daily
May-20-21 04:30PM	Arvinas to Present at the UBS Global Healthcare Virtual Conference GlobeNewswire
May-09-21 03:10AM	Industry Analysts Just Upgraded Their Arvinas, Inc. (NASDAQ:ARVN) Revenue Forecasts By 25% Simply Wall St.
May-04-21 02:52PM	Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven GlobeNewswire
08:45AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Apr-22-21 05:44PM	Arvinas Stock Clears Technical Benchmark With 80-Plus Relative Strength Rating Investor's Business Daily
Apr-19-21 01:38AM	Does Arvinas' (NASDAQ:ARVN) Share Price Gain of 27% Match Its Business Performance? Simply Wall St.
Apr-12-21 02:28PM	Is ARVN Stock A Buy or Sell? Insider Monkey
Apr-05-21 04:30PM	Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021 GlobeNewswire
Mar-10-21 04:30PM	Arvinas to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Mar-01-21 08:15AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:59AM	Arvinas: Q4 Earnings Insights Benzinga
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire
Feb-18-21 12:01AM	What Kind Of Shareholders Hold The Majority In Arvinas, Inc.'s (NASDAQ:ARVN) Shares? Simply Wall St.
Feb-08-21 04:30PM	Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day GlobeNewswire
Dec-28-20 04:30PM	Arvinas, Inc. Announces Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-23-20 04:40PM	3 Strong Buy Stocks Insiders Are Snapping Up TipRanks
Dec-16-20 01:37PM	Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More Zacks -10.51%
Dec-15-20 08:35PM	Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock GlobeNewswire +27.18%
07:48PM	Arvinas Cancer Drug Has Blockbuster Potential, Says Analyst TipRanks
09:48AM	ROCE Insights For Arvinas Benzinga
09:17AM	Arvinas (ARVN) Up on Promising Interim Data on Cancer Candidates Zacks
Dec-14-20 04:37PM	Why This Small Biotech Stock Nearly Doubled In Bullish Volume Investor's Business Daily +95.06%
04:06PM	Arvinas, Inc. Announces Proposed Offering of Common Stock GlobeNewswire
01:50PM	Arvinas Nearly Doubles on Promising Cancer Drug Results TheStreet.com
09:48AM	Return On Capital Employed Overview: Arvinas Benzinga
07:00AM	Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110 GlobeNewswire
Dec-11-20 04:15PM	Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs GlobeNewswire
Nov-25-20 07:00AM	Arvinas to Participate in Upcoming Virtual Investor Conferences GlobeNewswire
Nov-16-20 09:21AM	New Strong Sell Stocks for November 16th Zacks
Nov-07-20 07:43AM	Arvinas, Inc. (NASDAQ:ARVN) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Nov-05-20 07:00AM	Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
05:52AM	Rock star Growth Puts Arvinas (NASDAQ:ARVN) In A Position To Use Debt Simply Wall St.
Oct-14-20 07:00AM	Arvinas Announces Pipeline Programs Targeting Validated and Classically Undruggable Disease-Causing Proteins GlobeNewswire
Oct-06-20 05:17PM	Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit GlobeNewswire
Sep-15-20 11:42AM	Hedge Funds Have Never Been This Bullish On Arvinas, Inc. (ARVN) Insider Monkey
Sep-04-20 07:00AM	Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference GlobeNewswire
Aug-07-20 07:00AM	Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference GlobeNewswire
Aug-04-20 09:05AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.67%
07:00AM	Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Jul-30-20 08:45AM	The Arvinas (NASDAQ:ARVN) Share Price Has Gained 30% And Shareholders Are Hoping For More Simply Wall St.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morrison Briggs	Director	Apr 14	Option Exercise	16.00	16,188	259,008	40,936	Apr 18 09:00 PM
Morrison Briggs	Director	Apr 14	Sale	66.44	20,960	1,392,616	19,976	Apr 18 09:00 PM
Cassidy Sean A	Chief Financial Officer	Mar 11	Option Exercise	16.00	15,000	240,000	176,447	Mar 15 08:00 PM
Cassidy Sean A	Chief Financial Officer	Mar 11	Sale	70.00	15,000	1,050,000	161,447	Mar 15 08:00 PM
Houston John G	President and CEO	Mar 04	Sale	63.94	6,024	385,175	843,820	Mar 04 09:00 PM
Cassidy Sean A	Chief Financial Officer	Mar 04	Sale	63.94	1,593	101,856	161,447	Mar 04 09:00 PM
Taylor Ian	Chief Scientific Officer	Mar 04	Sale	63.94	869	55,564	83,962	Mar 04 09:00 PM
Taylor Ian	Chief Scientific Officer	Mar 01	Option Exercise	16.00	3,500	56,000	82,145	Mar 03 09:00 PM
Taylor Ian	Chief Scientific Officer	Feb 15	Option Exercise	19.36	20,000	387,200	98,645	Feb 17 09:00 PM
Taylor Ian	Chief Scientific Officer	Feb 15	Sale	73.02	20,000	1,460,316	78,645	Feb 17 09:00 PM
Morrison Briggs	Director	Jan 14	Option Exercise	16.00	16,188	259,008	45,708	Jan 19 09:00 PM
Morrison Briggs	Director	Jan 14	Sale	65.55	20,960	1,374,021	24,748	Jan 19 09:00 PM
Peck Ronald	Chief Medical Officer	Dec 30	Option Exercise	41.53	20,000	830,600	25,402	Jan 04 09:00 PM
Peck Ronald	Chief Medical Officer	Dec 30	Sale	80.61	20,000	1,612,264	5,402	Jan 04 09:00 PM
Cassidy Sean A	Chief Financial Officer	Dec 17	Option Exercise	16.00	15,000	240,000	173,249	Dec 21 09:15 PM
Cassidy Sean A	Chief Financial Officer	Dec 17	Sale	70.00	15,000	1,050,000	158,249	Dec 21 09:15 PM
Ratcliffe Liam	Director	Dec 16	Sale	69.36	85,705	5,944,418	185,686	Dec 16 09:30 PM
Ratcliffe Liam	Director	Dec 15	Sale	66.81	113,536	7,584,964	271,391	Dec 16 09:30 PM
Ratcliffe Liam	Director	Dec 14	Sale	65.86	156,464	10,303,999	384,927	Dec 16 09:30 PM
Taylor Ian	Chief Scientific Officer	Nov 15	Option Exercise	17.31	20,000	346,188	98,645	Nov 17 08:30 PM
Taylor Ian	Chief Scientific Officer	Nov 15	Sale	84.04	20,000	1,680,746	78,645	Nov 17 08:30 PM
Ratcliffe Liam	Director	Nov 15	Sale	84.87	21,284	1,806,469	541,391	Nov 15 09:45 PM
Ratcliffe Liam	Director	Nov 12	Sale	84.94	39,869	3,386,461	562,675	Nov 15 09:45 PM
Ratcliffe Liam	Director	Nov 11	Sale	86.23	59,799	5,156,393	602,544	Nov 15 09:45 PM
Ratcliffe Liam	Director	Nov 10	Sale	88.20	13,358	1,178,188	662,343	Nov 15 09:45 PM
Ratcliffe Liam	Director	Nov 09	Sale	91.97	33,008	3,035,861	675,701	Nov 09 09:47 PM
Ratcliffe Liam	Director	Nov 08	Sale	94.45	81,054	7,655,882	708,709	Nov 09 09:47 PM
Ratcliffe Liam	Director	Nov 05	Option Exercise	29.56	18,423	544,531	24,923	Nov 09 09:47 PM
Ratcliffe Liam	Director	Nov 05	Sale	91.84	33,094	3,039,319	789,763	Nov 09 09:47 PM
Ratcliffe Liam	Director	Nov 05	Sale	91.30	24,923	2,275,362	0	Nov 09 09:47 PM
Houston John G	President and CEO	Nov 01	Option Exercise	16.00	40,000	640,000	872,333	Nov 03 09:46 PM
Houston John G	President and CEO	Nov 01	Sale	88.14	40,000	3,525,724	832,333	Nov 03 09:46 PM
SHANNON TIMOTHY M	Director	Sep 07	Sale	89.09	36,411	3,243,796	1,653,128	Sep 27 02:22 PM
SHANNON TIMOTHY M	Director	Sep 03	Sale	85.53	32,387	2,770,146	1,689,539	Sep 27 02:22 PM
Houston John G	President and CEO	Sep 02	Option Exercise	16.00	4,690	75,040	832,333	Sep 07 08:00 PM
SHANNON TIMOTHY M	Director	Sep 02	Sale	85.83	51,765	4,443,116	1,721,926	Sep 27 02:19 PM
SHANNON TIMOTHY M	Director	Sep 01	Sale	87.05	79,437	6,915,221	1,773,691	Sep 27 02:19 PM
SHANNON TIMOTHY M	Director	Aug 31	Sale	85.56	59,355	5,078,151	1,853,128	Sep 27 02:19 PM
SHANNON TIMOTHY M	Director	Aug 30	Sale	86.07	58,838	5,064,458	1,912,483	Sep 27 02:18 PM
SHANNON TIMOTHY M	Director	Aug 27	Sale	85.42	45,026	3,845,951	1,971,321	Sep 27 02:18 PM
SHANNON TIMOTHY M	Director	Aug 26	Sale	85.12	11,712	996,970	2,016,347	Sep 27 02:18 PM
Margus Bradley Albert	Director	Aug 26	Sale	85.03	9,940	845,168	2,000	Aug 27 04:29 PM
Margus Bradley Albert	Director	Aug 25	Sale	85.00	20,000	1,700,000	11,940	Aug 27 04:29 PM
SHANNON TIMOTHY M	Director	Aug 25	Sale	85.03	14,267	1,213,144	2,028,059	Sep 27 02:16 PM
SHANNON TIMOTHY M	Director	Aug 24	Sale	87.02	9,203	800,818	2,042,326	Sep 27 02:16 PM
SHANNON TIMOTHY M	Director	Aug 23	Sale	88.01	1,599	140,728	2,051,529	Sep 27 02:16 PM
Taylor Ian	Chief Scientific Officer	Aug 16	Option Exercise	16.00	20,000	320,000	98,645	Aug 18 09:05 PM
Taylor Ian	Chief Scientific Officer	Aug 16	Sale	87.30	20,000	1,745,917	78,645	Aug 18 09:05 PM
Margus Bradley Albert	Director	Aug 13	Sale	90.03	5,828	524,695	31,940	Aug 13 09:00 PM
Peck Ronald	Chief Medical Officer	Aug 12	Sale	90.54	1,363	123,399	5,402	Aug 16 09:00 PM
Margus Bradley Albert	Director	Aug 11	Sale	90.03	5,000	450,150	37,768	Aug 13 09:00 PM
Houston John G	President and CEO	Aug 02	Option Exercise	16.00	45,922	734,752	873,565	Aug 04 08:05 PM
Houston John G	President and CEO	Aug 02	Sale	97.83	45,922	4,492,415	827,643	Aug 04 08:05 PM
Cassidy Sean A	Chief Financial Officer	Jul 28	Option Exercise	16.00	17,242	275,872	175,491	Jul 30 08:05 PM
Cassidy Sean A	Chief Financial Officer	Jul 28	Sale	100.00	17,242	1,724,200	158,249	Jul 30 08:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience